Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 100

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 100
---
 public shareholders that acquired their securities at higher prices. For example, based on the closing price of our Common Stock of $6.47 per share as of July 23, 2025, the shares purchased by the Sponsor would experience a potential profit of up to approximately $6.466 per share with respect to sales of the Common Stock received in consideration of the founder shares; |

| ● | the realization of any of the risk factors presented in this prospectus; |

| ● | the concentration of the ownership of our shares by a limited number of affiliated stockholders may limit interest in our securities; |

| ● | limited “public float” with a small number of persons whose sales or lack of sales could result in positive or negative pricing pressure on the market price for the Common Stock; |

| ● | additions or departures of key personnel; |

| ● | loss of a strategic relationship; |

| ● | variations in operating results from the expectations of securities analysts or investors; |

| ● | announcements of new products or services by us or our competitors; |

| ● | announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; |

| ● | investor perception of our industry or prospects; |

| ● | insider selling or buying; |

60

| ● | investors entering into short sale contracts; |

| ● | regulatory developments affecting our industry; |

| ● | changes in our industry; |

| ● | competitive pricing pressures; |

| ● | our ability to obtain working capital financing; |

| ● | our ability to execute our business plan; |

| ● | operating results that fall below expectations; |

| ● | revisions in securities analysts’ estimates or reductions in security analysts’ coverage; and |

| ● | economic and other external factors. |

Many of these factors are beyond our control and may decrease the market price of the Common Stock, regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for the Common Stock will be at any time, including as to whether the Common Stock will sustain current market prices, or as to what effect that the sale of shares or the availability of the Common Stock for sale at any time will have on the prevailing market price. In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of the Common Stock. In the past, many companies that have experienced volatility in the